Acumen Pharmaceuticals (ABOS) Short-term Investments (2021 - 2026)

Acumen Pharmaceuticals' Short-term Investments history runs 6 years deep, the most recent figure standing at $76.6 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 35.62% year-over-year to $76.6 million; the TTM figure through Mar 2026 stood at $76.6 million (down 35.62% YoY), while the FY2025 annual figure was $62.9 million, down 53.74% from the prior year.
• Short-term Investments came in at $76.6 million for Q1 2026 at Acumen Pharmaceuticals, up from $62.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $205.6 million in Q1 2024 to a low of $42.7 million in Q3 2022.
• A 5-year average of $107.2 million and a median of $80.3 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 271.83% in 2023 and slumped 53.74% in 2025, its largest moves.
• Acumen Pharmaceuticals' Short-term Investments stood at $47.5 million in 2022, then soared by 271.83% to $176.6 million in 2023, then declined by 23.05% to $135.9 million in 2024, then plunged by 53.74% to $62.9 million in 2025, then gained by 21.83% to $76.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $76.6 million, $62.9 million, and $79.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison